复发卵巢癌姑息治疗的目的是控制疾病相关症状、降低治疗的副反应,延长生存期,延迟病情进展的时间,维持或更好地提高生存质量。 复发卵巢癌首次铂类化疗的无治疗间期长短明显影响患者再接受铂类化疗的缓解率。铂类难治性卵巢癌(6个月内复发)再接受铂类治疗的缓解率约10％而铂类敏感者(6个月后复发)达28％。复发卵巢癌常使用铂类、紫杉醇联合化疗,但此方案对无治疗问期短者,缓解率低。无铂类问期与二线铂类联合联合化疗的缓解率有关:6～12个月者再化疗缓解率为25％～30％。2年者再化疗缓解率升至60％～70％。卡铂、 The purpose of palliative treatment of recurrent ovarian cancer is to control disease-related symptoms, reduce the side effects of treatment, prolong survival, delay the progression of the disease, maintain or improve the quality of life. The first non-treatment interval of platinum chemotherapy in recurrent ovarian cancer significantly affects the remission rate of patients receiving platinum-based chemotherapy. The platinum-refractory ovarian cancer (relapse within 6 months) re-treated with platinum had a response rate of about 10% and the platinum-sensitive (relapse 6 months later) reached 28%. Recurrence of ovarian cancer often use platinum, paclitaxel combined with chemotherapy, but this program is no treatment for those with short response, low response rate. Platinum-free questioning period and second-line platinum combined with chemotherapy response rate: 6 ~ 12 months re-chemotherapy remission rate of 25% to 30%. 2 years of re-chemotherapy remission rate rose to 60% to 70%. Carboplatin,